Carmichael Hill & Associates’s Globus Medical GMED Stock Holding History

Carmichael Hill & Associates’s Portfolio GMED Stock Details GMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-300	Closed	-$16K	–	784
2023 Q4	$16K	Hold	300	–	–	0.01%	510
2023 Q3	$14.9K	Hold	300	–	–	0.01%	502
2023 Q2	$17.9K	Hold	300	–	–	0.01%	487
2023 Q1	$17K	Hold	300	–	–	0.01%	480
2022 Q4	$22.3K	Hold	300	–	–	0.01%	450
2022 Q3	$18K	Hold	300	–	–	0.01%	488
2022 Q2	$17K	Sell	300 -400	-57%	-$26.3K	0.01%	492
2022 Q1	$52K	Hold	700	–	–	0.02%	350
2021 Q4	$51K	Hold	700	–	–	0.02%	361
2021 Q3	$54K	Hold	700	–	–	0.03%	340
2021 Q2	$54K	Hold	700	–	–	0.03%	336
2021 Q1	$43K	Hold	700	–	–	0.02%	360
2020 Q4	$46K	Hold	700	–	–	0.03%	335
2020 Q3	$35K	Hold	700	–	–	0.02%	344
2020 Q2	$33K	Buy	+700	New	+$33.8K	0.02%	341

Other funds holding GMED

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BAM

Burgundy Asset Management Toronto, Ontario, Canada $10.6B AUM 13.39% 1-Year Est. Return

HRCM

Hawk Ridge Capital Management Los Angeles, California $2.75B AUM 20.09% 1-Year Est. Return

Carmichael Hill & Associates's GMED Position: Q1 2024 in Review

Carmichael Hill & Associates sold out of Globus Medical (GMED) in Q1 2024, closing a stake of 300 shares — an estimated $16K sold.

Carmichael Hill & Associates first reported a position in GMED in Q2 2020 and held it in 15 quarters. The position peaked at $54K in Q3 2021. 439 funds tracked by Wall St. Rank hold GMED as of Q1 2024.

Carmichael Hill & Associates reported no remaining Globus Medical position as of Q1 2024 after selling out during the quarter.
Carmichael Hill & Associates sold 300 Globus Medical shares in Q1 2024, an estimated $16K.
Carmichael Hill & Associates first reported a position in Globus Medical in Q2 2020 and held it in 15 quarters.
Carmichael Hill & Associates's Globus Medical position peaked at $54K in Q3 2021.
439 funds tracked by Wall St. Rank held Globus Medical as of Q1 2024.

Based on Carmichael Hill & Associates's 13F filing for Q1 2024, filed 24 Apr 2024.